Table 3. Covariate analysis of DACH1 mutated patients compared to wild-type.
| Covariates | DACH1 | ||
|---|---|---|---|
| WT N = 53 | M N = 12 | P-valuea | |
| Age | 61.15 ± 11.25 | 66.50 ± 7.35 | 0.05267 |
| BMI | 36.91±10.65 | 34.03±8.03 | 0.3047 |
| Race | 0.3746 | ||
| Caucasian | 49 (75.4%) | 10 (15.4%) | |
| African American | 3 (4.6%) | 2 (3.1%) | |
| Asian | 1 (1.5%) | 0 (0.0%) | |
| Grade | 0.9121 | ||
| 1 | 17 (32%) | 3 (25%) | |
| 2 | 10 (18.8%) | 2 (16.7%) | |
| 3 | 26 (49%) | 7 (58.3%) | |
| Clinical stage | 0.4144 | ||
| I | 23 (43.4%) | 8 (66.7%) | |
| II | 5 (9.4%) | 0 (0.0%) | |
| III | 13 (24.5%) | 1 (8.3%) | |
| IV | 10 (18.9%) | 2 (16.7%) | |
| Unknown | 2 (3.8%) | 1 (8.3%) | |
| Clinical stage, early vs. late | 0.3316 | ||
| Early stage (I-II) | 28 (52.8%) | 8 (66.7%) | |
| Late stage (III-IV) | 23 (43.4%) | 3 (25%) | |
| Unknown | 2 (3.8%) | 1 (8.3%) | |
| Tobacco use (smoking) | 1 | ||
| No | 35 (66%) | 8 (66%) | |
| Yes | 17 (32%) | 4 (6.2%) | |
| Unknown | 1 (1.9%) | 0 (0%) | |
| Documented recurrence | 1 | ||
| No | 33 (50.8%) | 9 (13.8%) | |
| Yes | 13 (20.0%) | 3 (4.6%) | |
| Unknown | 7 (13.2%) | 0 (0%) | |
| Appalachian status | 1 | ||
| Non-Appalachian | 20 (30.8%) | 5 (7.7%) | |
| Appalachian | 33 (50.8%) | 7 (10.8%) | |
| Histologic subtypeb | 0.9473 | ||
| Endometrioid | 31 (47.7%) | 6 (9.23%) | |
| Mixed cell adenocarcinoma | 4 (6.2%) | 1 (1.5%) | |
| Carcinosarcoma | 5 (7.7%) | 1 (1.5%) | |
| Serous | 12 (18.5%) | 3 (4.6%) | |
a P-values were calculated using the Fisher’s exact test for categorical variables and using the student t-test for continuous variables.
b Single cases each of malignant mesonephroma (DACH1 mutated) and clear cell carcinoma (DACH1 wild-type) excluded from covariate analysis.